ALK and lung carcinoma: Moreover, some ubiquitination sites on the ATP1A1 and SLC3A2 transporters were upregulated, suggesting that, in ALK-driven lung cancer cells, stabilization of these transporters may not play a significant role in the metabolic changes induced by TKI treatment.